Phoenix, Arizona--(Newsfile Corp. - December 19, 2019) - The Stock Day Podcast welcomed Tetra Bio-Pharma (OTC: TBPMF) ("the Company"), a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada authorized, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. CEO of the Company, Dr. Guy Chamberland, joined Stock Day host Everett Jolly.

Jolly began the interview by asking about the Company's current therapies. "Our lead product is called CAUMZ™," explained Dr. Chamberland, noting that this drug represents the second generation of their original drug, PPP001. "We were very successful in being able to develop the second generation," shared Dr. Chamberland, adding that the Company also developed intellectual property during this time. "This lead to the creation of the PPP011, which is a synthetic version and is highly purified," he added.

Dr. Chamberland then expanded on the Company's additional drugs and treatments, including HCC011. This drug was developed for the treatment of hepatocellular carcinoma and was derived from PPP011, allowing for an easier and more cost effective manufacturing process. "Our last program is our ophthalmics program, which is called PPP003," said Dr. Chamberland. "Now we're finalizing the IND enabling studies, which is the data we need to be allowed to go into Phase II," he shared, adding that the Company will likely begin human testing for this drug in Q3.

Jolly then asked about the potential of cannabinoids in the healthcare industry. Dr. Chamberland shared that the potential of cannabinoids is exceptional and elaborated on the Company's strategy to develop inhaled cannabis based drugs. "This is the advantage to what we've done. We've recreated what was inhaled synthetically," said Dr. Chamberland.

"The next step for us is finalizing our plans to scale up to a commercial level," shared Dr. Chamberland, adding that the Company will also move forward with the production of PPP011. "The next step will be getting the clinical data - if it's favorable, which we strongly believe it will be, then afterwards it's just putting together the marketing application," said Dr. Chamberland. He also noted that this would make the Company the first in the industry to bring a cannabinoid-inhaled drug to the market.

Jolly then asked about the Company's FDA Orphan Drug Designation for the treatment of hepatocellular carcinoma. "The Orphan Drug is for the ability of THC to act as an anti-cancer - basically to stop the progression of tumors," explained Dr. Chamberland, noting that THC has also been recognized to treat symptoms of nausea, vomiting, and loss of appetite in cancer patients.

To close the interview, Dr. Chamberland shared that the Company has spent significant time developing a portfolio of intellectual property, adding that the applications for these technologies include chronic pain and inflammation in the opthalmic space. "We've also created several joint ventures," shared Dr. Chamberland. "I think in the long run being 50% owners of even our joint ventures will bring a lot of rewards to our shareholders," closed Dr. Chamberland.

To hear Dr. Guy Chamberland's entire interview, follow the link to the podcast here:

is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at

About Tetra Bio-Pharma

Tetra Bio-Pharma (TSXV: TBP) (OTC: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit:

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research and development strategies, including the success of this product or any other product, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.:

Investor Contact:
Bruce Mackle
LifeSci Advisors LLC
646-889-1200

Media Contact:
Andrew Mielach
LifeSci Public Relations
646-876-5868

Canada:
Carol Levine
Energi PR
514-288-8500 ext. 226

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.

SOURCE:
Stock Day Media
602-441-3474

To view the source version of this press release, please visit